Alto Neuroscience (NYSE:ANRO) Issues Earnings Results, Beats Expectations By $0.09 EPS

Alto Neuroscience (NYSE:ANRO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09, Zacks reports.

Alto Neuroscience Stock Performance

NYSE:ANRO traded down $0.01 during trading hours on Monday, reaching $2.65. The company had a trading volume of 225,561 shares, compared to its average volume of 359,915. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. Alto Neuroscience has a 1-year low of $2.58 and a 1-year high of $18.35. The business's 50 day moving average price is $3.63 and its 200-day moving average price is $6.05. The firm has a market cap of $71.34 million and a PE ratio of -1.04.

Analyst Ratings Changes

Separately, William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a report on Friday. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Alto Neuroscience presently has an average rating of "Moderate Buy" and an average target price of $16.75.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.